Compositions and Methods for Treatment of Cancer
First Claim
1. A pyrroloquinolinyl-pyrrolidine-2,5-dione compound of formula IVa, IVb, Va, or Vb, or pharmaceutically acceptable salts thereof:
- where;
R1, R2 and R3 are independently selected from the group consisting of hydrogen, F, Cl, Br, I, —
NR5R6, —
(C1-C6) alkyl, —
(C1-C6) substituted alkyl, —
(C3-C9) cycloalkyl, —
(C3-C9) substituted cycloalkyl, —
O—
(C1-C6) alkyl, —
O—
(C1-C6) substituted alkyl, —
O—
(C3-C9) cycloalkyl, and —
O—
(C3-C9) substituted cycloalkyl, aryl, heteroaryl, heterocyclyl;
R4 is independently selected from the group consisting of hydrogen, —
(C1-C6) alkyl, —
CH2R7;
R5, R6 are independently selected from the group consisting of hydrogen, and —
(C1-C6) alkyl;
R7 is independently selected from the group consisting of —
O—
P(═
O)(OH)2, —
O—
P(═
O)(—
OH)(—
O—
(C1-C6) alkyl), —
O—
P(═
O)(—
O—
(C1-C6) alkyl)2, —
O—
P(═
O)(—
OH) (—
O—
(CH2)-phenyl), —
O—
P(═
O)(—
O—
(CH2)-phenyl)2, a carboxylic acid group, an amino carboxylic acid group and a peptide;
Q is selected from the group consisting of aryl, heteroaryl, —
O-aryl, —
S-aryl, —
O-heteroaryl, and —
S-heteroaryl;
X is —
(NR8)-;
R8 is independently selected from the group consisting of hydrogen, —
(C1-C6) alkyl, —
(C1-C6) substituted alkyl, —
(C3-C9) cycloalkyl, —
(C3-C9) substituted cycloalkyl, and —
O—
(C1-C6) alkyl, —
C(═
O)—
O—
(C1-C6) alkyl and —
C(═
O)—
O—
(C1-C6) substituted alkyl;
Y is (CH2)—
;
wherein said aryl, heteroaryl, —
O-aryl, —
S-aryl, —
O-heteroaryl, and —
S-heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, I, —
NR5R6, —
(C1-C6) alkyl, —
(C1-C6) substituted alkyl, —
(C3-C9) cycloalkyl, —
(C3-C9) substituted cycloalkyl, —
O—
(C1-C6) alkyl, —
O—
(C1-C6) substituted alkyl, —
O—
(C3-C9) cycloalkyl, —
O—
(C3-C9) substituted cycloalkyl, -aryl, -aryl-(C1-C6) alkyl, -aryl-O—
(C1-C6) alkyl, —
O-aryl, —
O—
(C1-C4) alkyl-aryl, heteroaryl, heterocyclyl, —
O—
(C1-C4) alkyl-heterocycle, and —
(S(═
O)2)—
(C1-C6) alkyl; and
m is 1.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.
-
Citations
35 Claims
-
1. A pyrroloquinolinyl-pyrrolidine-2,5-dione compound of formula IVa, IVb, Va, or Vb, or pharmaceutically acceptable salts thereof:
-
where; R1, R2 and R3 are independently selected from the group consisting of hydrogen, F, Cl, Br, I, —
NR5R6, —
(C1-C6) alkyl, —
(C1-C6) substituted alkyl, —
(C3-C9) cycloalkyl, —
(C3-C9) substituted cycloalkyl, —
O—
(C1-C6) alkyl, —
O—
(C1-C6) substituted alkyl, —
O—
(C3-C9) cycloalkyl, and —
O—
(C3-C9) substituted cycloalkyl, aryl, heteroaryl, heterocyclyl;R4 is independently selected from the group consisting of hydrogen, —
(C1-C6) alkyl, —
CH2R7;R5, R6 are independently selected from the group consisting of hydrogen, and —
(C1-C6) alkyl;R7 is independently selected from the group consisting of —
O—
P(═
O)(OH)2, —
O—
P(═
O)(—
OH)(—
O—
(C1-C6) alkyl), —
O—
P(═
O)(—
O—
(C1-C6) alkyl)2, —
O—
P(═
O)(—
OH) (—
O—
(CH2)-phenyl), —
O—
P(═
O)(—
O—
(CH2)-phenyl)2, a carboxylic acid group, an amino carboxylic acid group and a peptide;Q is selected from the group consisting of aryl, heteroaryl, —
O-aryl, —
S-aryl, —
O-heteroaryl, and —
S-heteroaryl;X is —
(NR8)-;R8 is independently selected from the group consisting of hydrogen, —
(C1-C6) alkyl, —
(C1-C6) substituted alkyl, —
(C3-C9) cycloalkyl, —
(C3-C9) substituted cycloalkyl, and —
O—
(C1-C6) alkyl, —
C(═
O)—
O—
(C1-C6) alkyl and —
C(═
O)—
O—
(C1-C6) substituted alkyl;Y is (CH2)—
;wherein said aryl, heteroaryl, —
O-aryl, —
S-aryl, —
O-heteroaryl, and —
S-heteroaryl groups may be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, I, —
NR5R6, —
(C1-C6) alkyl, —
(C1-C6) substituted alkyl, —
(C3-C9) cycloalkyl, —
(C3-C9) substituted cycloalkyl, —
O—
(C1-C6) alkyl, —
O—
(C1-C6) substituted alkyl, —
O—
(C3-C9) cycloalkyl, —
O—
(C3-C9) substituted cycloalkyl, -aryl, -aryl-(C1-C6) alkyl, -aryl-O—
(C1-C6) alkyl, —
O-aryl, —
O—
(C1-C4) alkyl-aryl, heteroaryl, heterocyclyl, —
O—
(C1-C4) alkyl-heterocycle, and —
(S(═
O)2)—
(C1-C6) alkyl; andm is 1. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 11, 14, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)
-
-
10. (canceled)
-
12-13. -13. (canceled)
-
15. (canceled)
-
17. The pharmaceutical composition of 16, wherein said second chemotherapeutic agent is selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, trastuzumab, imatinib, paclitaxel, cyclophosphamide, lovastatin, mimosine, gemcitabine, araC, 5-fluorouracil, methotrexate, docetaxel, goserelin, vinctristine, vinblastine, nocodazole, teniposide, etoposide, gemcitabine, epothilone, navelbine, camptothecin, daunorubicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin, epirubicin or idarubicin.
Specification